Physician profile
John E Caswell
NPI 1336198365
$7,280.36
in general payments reported to CMS, 2019-2025
36 companies · $697 in 2025
The $697 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $1,058 · 2021: $1,743 · 2022: $1,351 · 2023: $1,178 · 2024: $645 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,110.99 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $844.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $627.08 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $617.99 | 2021-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $558.26 | 2021-2024 | |
| Glaxosmithkline, LLC. | $455.99 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $341.53 | 2019-2023 | |
| Abbott Laboratories | $319.81 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Lilly USA, LLC | $233.37 | 2021-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $230.46 | 2022-2024 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $226.55 | 2019-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.15 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $157.63 | 2021-2022 | |
| Dexcom, INC. | $141.21 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $124.96 | 2020-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Caswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.